

## STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN AB-19

FALDAPREVIR

PRONUNCIATION

fal da' pre vir


THERAPEUTIC CLAIM

Treatment of chronic Hepatitis C infection

## CHEMICAL NAMES

1. Cyclopropanecarboxylic acid, *N*-[(cyclopentyloxy)carbonyl]-3-methyl-*L*-valyl-(4*R*)-4-[[8-bromo-7-methoxy-2-[2-[(2-methyl-1-oxopropyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-*L*-proyl-1-amino-2-ethenyl-, (1*R*,2*S*)-
2. (1*R*,2*S*)-1-[[[(2*S*,4*R*)-4-[[8-bromo-7-methoxy-2-[2-(2-methylpropanamido)-1,3-thiazol-4-yl]quinolin-4-yl]oxy]-1-[(2*S*)-2-[[[(cyclopentyloxy)carbonyl]amino]-3,3-dimethylbutanoyl]pyrrolidine-2-carboxamido]-2-ethenylcyclopropane-1-carboxylic acid

## STRUCTURAL FORMULA



MOLECULAR FORMULA

C<sub>40</sub>H<sub>49</sub>BrN<sub>6</sub>O<sub>9</sub>S

MOLECULAR WEIGHT

869.8

TRADEMARK

None as yet

SPONSOR

Boehringer Ingelheim Pharmaceuticals, Inc.

CODE DESIGNATION

BI 201335

CAS REGISTRY NUMBER

801283-95-4

WHO NUMBER

9497

SCS